D.E. Shaw & Co
MRTX

D.E. Shaw & Co’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

D.E. Shaw & Co’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-50,000
Closed -$7.33M – 6087
2021
Q4 		$7.33M Hold
50,000
– – 0.01% 1979
2021
Q3 		$8.85M Hold
50,000
– – 0.01% 1608
2021
Q2 		$8.08M Hold
50,000
– – 0.01% 1676
2021
Q1 		$8.56M Sell
50,000
-30,200
-38% -$5.98M 0.01% 1464
2020
Q4 		$17.6M Buy
80,200
+20,000
+33% +$4.32M 0.02% 1025
2020
Q3 		$10M Buy
60,200
+10,000
+20% +$1.37M 0.01% 1247
2020
Q2 		$5.73M Buy
50,200
+10,000
+25% +$970K 0.01% 1565
2020
Q1 		$3.09M Buy
40,200
+10,000
+33% +$897K ﹤0.01% 1833
2019
Q4 		$3.89M Buy
30,200
+20,000
+196% +$1.93M ﹤0.01% 1929
2019
Q3 		$795K Buy
+10,200
New +$957K ﹤0.01% 2949
2019
Q1 		– Sell
-45,000
Closed -$1.91M – 4007
2018
Q4 		$1.91M Buy
+45,000
New +$1.79M ﹤0.01% 2189

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

D.E. Shaw & Co's MRTX Position: Q1 2024 in Review

D.E. Shaw & Co sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 7,693 shares — an estimated $452K sold.

D.E. Shaw & Co first reported a position in MRTX in Q3 2015 and held it in 25 quarters. The position peaked at $39.6M in Q3 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • D.E. Shaw & Co reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 7,693 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $452K.
  • D.E. Shaw & Co first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 25 quarters.
  • D.E. Shaw & Co's Mirati Therapeutics, Inc. Common Stock position peaked at $39.6M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.